Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Business & Finance

Reuters was two-and-a-half minutes ahead^[1] of rivals on Eli Lilly’s unscheduled trading update, which showed fourth-quarter sales of its weight-loss drug Zepbound would miss Wall Street estimates. The drugmaker’s shares slumped 8% on

Read more https://www.reutersagency.com/en/reutersbest/article/lilly-shares-on-track-for-worst-day-since-2021-after-downbeat-zepbound-sales-forecast/